Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD-Reference-Cited by-同舟云学术

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

Published:2013-12-12 Issue:25 Volume:122 Page:4111-4118
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Olivieri Attilio¹,Cimminiello Michele²,Corradini Paolo³,Mordini Nicola⁴,Fedele Roberta⁵,Selleri Carmine⁶,Onida Francesco⁷,Patriarca Francesca⁸,Pavone Enzo⁹,Svegliati Silvia¹⁰,Gabrielli Armando¹⁰,Bresciani Paola¹¹,Nuccorini Roberta²,Pascale Sara²,Coluzzi Sabrina²,Pane Fabrizio¹²,Poloni Antonella¹,Olivieri Jacopo¹³,Leoni Pietro¹,Bacigalupo Andrea¹⁴

Affiliation:

1. Clinica di Ematologia, Università Politecnica delle Marche, Ancona, Italy;

2. U.O. di Ematologia Centro Trapianto di Cellule Staminali, Azienda Ospedaliera Regionale San Carlo, Potenza, Italy;

3. Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Università di Milano, Milan, Italy;

4. Divisione di Ematologia, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy;

5. Divisione di Ematologia e TMO, Ospedale Bianchi-Melacrino-Morelli, Reggio Calabria, Italy;

6. U.O.C. di Ematologia, Dipartimento di Medicina e Chirurgia, Università degli Studi di Salerno, Salerno, Italy;

7. Divisione di Ematologia, Fondazione IRCCS Ca’Granda, Milan, Italy;

8. Clinica Ematologica, A.O.U. Santa Maria della Misericordia, Udine, Italy;

9. Dipartimento di Ematologia-Centro Trapianti Midollo Osseo, Azienda Ospedaliera Card. G. Panico, Tricase, Italy;

10. Clinica Medica, Università Politecnica delle Marche, Ancona, Italy;

11. Ematologia, Azienda Ospedaliero Universitaria Policlinico, Modena, Italy;

12. Divisione di Ematologia, Università degli Studi di Napoli Federico II, Naples, Italy;

13. Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; and

14. Divisione di Ematologia II, Azienda Ospedaliera Universitaria “S. Martino,” Genova, Italy

Abstract

Key Points Efficacy of imatinib in steroid-refractory chronic GVHD was prospectively compared across 3 different response systems, with high agreement. Validity of quantitative-based assessment of response with NIH criteria was confirmed by its prognostic impact on long-term survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/25/4111/1371473/4111.pdf

Reference33 articles.

1. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.;Wolff;Biol Blood Marrow Transplant,2011

2. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.;Arai;Blood,2011

3. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.;Pidala;Blood,2011

4. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.;Jacobsohn;Blood,2012

5. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.;Martires;Blood,2011

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease;Blood Reviews;2024-01

2. Targeting PRMT1 prevents acute and chronic graft-versus-host disease;Molecular Therapy;2023-11

3. Chronic graft-versus-host disease in pediatric patients: Differences and challenges;Blood Reviews;2023-07

4. Complex interactions of cellular players in chronic Graft-versus-Host Disease;Frontiers in Immunology;2023-06-26

5. Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction;Pharmacological Reviews;2023-06-09